- Home
- KLRS vs NRXS Comparison
KLRS vs NRXS Comparison
Compare KLRS & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KLRS | NRXS |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.0M | 44.7M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | KLRS | NRXS |
|---|---|---|
| Price | $8.32 | $4.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $20.67 | $8.00 |
| AVG Volume (30 Days) | 174.7K | ★ 899.5K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,362,320.00 |
| Revenue This Year | N/A | $31.05 |
| Revenue Next Year | N/A | $137.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 36.89 |
| 52 Week Low | $2.14 | $1.33 |
| 52 Week High | $12.90 | $6.20 |
Technical Indicators
Market Signals| Indicator | KLRS | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 53.42 | 73.77 |
| Support Level | $8.31 | $2.63 |
| Resistance Level | $9.45 | $4.70 |
| Average True Range (ATR) | 1.07 | 0.39 |
| MACD | -0.19 | 0.16 |
| Stochastic Oscillator | 14.78 | 88.48 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).